Efficacy and tolerance of 400 mg Bezafibrate in diabetic and hyperlipidaemic patients

J. Lakatos, M. Molnár, K. Tóth

Research output: Contribution to journalArticle


The authors report the results of an open clinical study using 400 mg Bezafibrate once a day. Among 25 diabetic patients (type II.) underwent a 4 weeks period with nutritional advice. Average changes from inclusion levels were -24% for total cholesterol, -56% for triglicerides, +11.9% for HDL-cholesterol, -19% for plama fibrinogen In conclusion, bezafibrate at a daily dose of 400 mg had significant lipid-modifying properties but also exhibited a beneficial effect on other related risk factors such as fibrinogen reduction.

Original languageEnglish
Pages (from-to)433-435
Number of pages3
JournalActa physiologica Hungarica
Issue number4
Publication statusPublished - Dec 1 1996



  • Bezafibrate
  • Fibrinogen
  • Lipoproteins
  • Risk factors

ASJC Scopus subject areas

  • Physiology (medical)

Cite this